Brief: Metacrine Accelerates MET409 Clinical Development Milestone And Reports First-Quarter 2021 Results
13/05/2021 22:37
May 13 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE ACCELERATES MET409 CLINICAL DEVELOPMENT
MILESTONE AND
REPORTS FIRST-QUARTER 2021 RESULTS
* METACRINE, INC. - NET LOSS WAS $14.8 MILLION FOR THREE
MONTHS
ENDED MARCH 31, 2021, AS COMPARED TO $8.1 MILLION FOR PRIOR-YEAR
QUARTER
Source text for Eikon: ID:nGNX2QsWvP
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions